Established thrombotic risk factors commonly present in semaglutide users include: Obesity (BMI 30 kg/m), which increases VTE risk 2-3 fold [13] Type 2 diabetes and insulin resistance Prolonged immobility or sedentary lifestyle History of previous blood clots Active cancer or recent cancer treatment Recent surgery, particularly orthopedic or abdominal procedures Smoking Certain medications, including estrogen-containing contraceptives or hormone replacement therapy Inherited thrombophilias (clotting disorders) Advanced age (risk increases after age 60) Pregnancy and postpartum period (note that semaglutide should be discontinued when pregnancy is recognized) Patients initiating semaglutide should undergo comprehensive baseline assessment including medical history review, with particular attention to prior thrombotic events and family history of clotting disorders
Screens were analyzed using Python (v.2.7.13), R (v.3.3.2) and Unix (v.4.10.0-37-generic x86_64)
Growth Factor Signaling BPC-157 appears to upregulate growth hormone receptor expression in fibroblasts and modulate multiple growth factor pathways including EGF, FGF, and VEGF (Sikiric et al., 2018)
Fiber: Found in fruits, vegetables, beans, lentils, chia seeds, and whole grains, fiber keeps digestion regular and helps you feel fuller longer
FDA Advisory Committees
A.OstroveJ
